These crawls are part of an effort to archive pages as they are created and archive the pages that they refer to. That way, as the pages that are referenced are changed or taken from the web, a link to the version that was live when the page was written will be preserved.Then the Internet Archive hopes that references to these archived pages will be put in place of a link that would be otherwise be broken, or a companion link to allow people to see what was originally intended by a page's authors.The goal is to fix all broken links on the web . Crawls of supported "No More 404" sites. ||||| (Reuters) - Drugmaker KaloBios Pharmaceuticals Inc KBIO.O said it fired Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of a securities fraud. 
 
 Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs the U.S. Federal Court after an arraignment following him being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York December 17, 2015. REUTERS/Lucas Jackson 
 
 Shkreli, who has become the poster child for the issue of soaring prices for prescription medications, has already stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, in addition to resigning from KaloBios’ board of directors. 
 
 Shkreli was arrested last week for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund MSMB Capital Management and Retrophin Inc (RTRX.O), a company he headed before he took the helm of Turing Pharmaceuticals. 
 
 After buying a 60-year-old anti-infective drug often used by AIDS patients earlier this year, Turing raised the price overnight to $750 a tablet from $13.50. 
 
 The increase propelled Shkreli to the media spotlight: Presidential candidate Hillary Clinton pilloried him for gouging, and he was pulled into congressional drug pricing investigations. 
 
 The government charges do not include activities at privately held Turing. 
 
 Shkreli, who was arrested on Thursday and released soon after on a $5 million bond, said he has been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona, the Wall Street Journal reported on Monday. 
 
 “‘Trying to find anything we could to stop him’ was the attitude of the government,” Shkreli told the Journal in an interview, saying he was arrested because of a social experiment and teasing people over the Internet, deeming the arrest unjust. 
 
 An FBI spokeswoman declined to comment on the WSJ report. 
 
 In a separate incident, Shkreli lost control of his Twitter account to hackers on Sunday, hours after he took to the microblogging service to plead his innocence, said his spokesman, Craig Stevens. 
 
 Shkreli tweeted late Monday morning saying he had regained control of his account. (bit.ly/1OGnJeJ) 
 
 KaloBios, which was planning to shut shop, named Shkreli as its CEO on Nov. 20, after Shkreli and a consortium of investors bought about 70 percent of the company’s shares. 
 
 The drug developer said on Monday that Tony Chase, who was appointed to the company’s board along with Shkreli, had also resigned. 
 
 A class action lawsuit was filed on behalf of KaloBios shareholders on Friday in the United States district court in the Northern District of California. 
 
 It alleged that Shkreli made false and/or misleading statements, as well as failed to disclose material information about the company’s business. 
 
 Trading in KaloBios shares was halted on Monday for the third straight session. ||||| Martin Shkreli, the embattled health care businessman, has been let go by KaloBios Pharmaceuticals — one of the companies he had headed. 
 
 
 
 KaloBios, which has a market cap of less than $100 million, hasn't traded since last Thursday. It was halted about 10 minutes after news of Shkreli's arrest on fraud charges. 
 
 On Monday, the company said Shkreli was "terminated" as CEO and had resigned from the board.
– Notorious drug CEO/record-album purchaser Martin Shkreli has lost one of those descriptors. He resigned as CEO of Turing Pharmaceuticals on Friday following his Thursday arrest for alleged securities fraud and conspiracy, and Monday brings the news that he's been terminated as CEO of KaloBios Pharmaceuticals, reports CNBC. Reuters reports the move was effective on the day of Shkreli's arrest, which was also the day the company halted trading; trading has yet to resume. Shkreli has additionally given up his seat on KaloBios' board. But trading isn't the only thing that's been halted in relation to KaloBios. Bloomberg reports that a clinical leukemia drug trial sponsored by KaloBios has been suspended by the University of California at Davis and Florida's Moffitt Cancer Center. A number of additional institutions had also planned to participate—among them the Mayo Clinic and Weill Cornell Medical College. As of Saturday, they had yet to comment or announce a decision.